Chimerix Provides Update on Research and Development

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chimerix Provides Update on Research and Development Progress

DURHAM, N.C., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided an update on the company's R&D programs, including the addition of a potential new product candidate, CMX16669, to its development pipeline.

R&D Update Meeting Overview

  • Candidate Selection of CMX16669

    The company has discovered, developed and selected a novel clinical candidate, CMX16669, for BK virus and cytomegalovirus (CMV). This new product candidate has demonstrated potent in vitro activity against CMV and BK virus, with a promising safety profile in vitr o and in pilot toxicity studies in animals. The modified lipid tail may enable very low oral doses, based on initial animal studies. Chimerix plans to initiate clinical trials in 2015.

    Michael Rogers, PhD, Chief Development Officer, said, "Our team of virologists and chemists with extensive expertise in antiviral research has delivered a unique clinical candidate. Our discovery program is focused on leveraging our library of novel structures designed to hit antiviral targets, while harnessing our complementary drug delivery lipid technology which has a wide range of potential applications."
     
  • Brincidofovir for Ebola Virus Disease

    The company announced that it has worked closely with the FDA to develop a Phase 2 clinical trial protocol to assess the safety, tolerability, and efficacy of brincidofovir in patients who are confirmed to have Ebola Virus Disease. An investigational new drug (IND) application for brincidofovir (BCV) for Ebola Virus Disease (EVD) has been authorized by the FDA. The FDA has authorized a Phase 2 protocol for BCV for EVD to begin immediately. Brincidofovir tablets are available for immediate use in clinical trials.
     
  • AdVise, SUPPRESS and Smallpox Clinical Trials

    The company also reviewed positive brincidofovir data from the open-label pilot portion of AdVise, showing a potential survival benefit for patients with adenovirus infection. This was presented by Dr. Michael Grimley, Associate Professor, Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital. Additionally, the company reviewed its Phase 3 SUPPRESS trial for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant (bone marrow transplant), as well as the brincidofovir development program for the treatment of smallpox as a medical countermeasure due to a bioterror attack or accidental release.

About Brincidofovir (BCV, CMX001)

Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenoviruses. Brincidofovir has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date, side effects that can be treatment limiting with currently available antivirals. Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant (HCT) recipients. In addition, Chimerix is enrolling the pilot portion of the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus (AdV) infection. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com .

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Joseph T. Schepers Executive Director Investor Relations and Corporate Communications 919-287-4125

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading